Phase 1 and 2 Study of PX-866 and Cetuximab

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment. In the Phase 1 part of the study, the dose of PX-866 to be given in combination with cetuximab will be determined in patients with incurable metastatic CRC or incurable progressive, recurrent or metastatic SCCHN. The Phase 2 part of the study is a randomized evaluation of the antitumor activity and safety of PX-866 in combination with cetuximab versus cetuximab alone in patients with either incurable metastatic CRC who have a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens or are intolerant of irinotecan (Group 1) or incurable progressive, recurrent or metastatic SCCHN (Group 2).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cascadian Therapeutics Inc.
• Treatments: Cetuximab

Criteria

Inclusion Criteria:

• At least 18 years at time of consent

• Use of a medically accepted form of contraception from the time of consent to completion of all follow-up study visits

• If female of child-bearing potential, negative pregnancy test

• Signed an informed consent

• Measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST)

• Documentation available for last prior systemic treatment including dates of treatment, best response to treatment, duration of best response, and reason for discontinuation of treatment

• Eastern Cooperative Oncology Group (ECOG) 0 or 1

• Group 1: Patients with incurable metastatic CRC with a history of progression or recurrence following prior irinotecan and oxaliplatin containing regimens. Patients who have a history of intolerance of irinotecan based therapy or ineligibility to receive irinotecan are also eligible as long as they have received a prior oxaliplatin containing regimen.

• Group 2: Patients with incurable SCCHN with a history of progression or recurrence following at least one prior platinum based chemotherapy or chemotherapy/radiation containing regimen. Patients who have a history of intolerance of platinum based therapy or history of ineligibility to receive a platinum based regimen are also eligible. SCCHN patients who received cetuximab as a radiosensitizer for locally advanced disease and completed treatment at least 6 months prior to start of study drug treatment are eligible

• In the opinion of the clinical investigator, life expectancy of greater than 3 months

• Adequate hematologic function

• Adequate hepatic function

• Creatinine level ≤1.5 x ULN

• Serum magnesium ≥ LLN.

Exclusion Criteria:

• Has medical, social, or psychosocial factors that, in the opinion of the investigator, could impact safety or compliance with study procedures

• Is breastfeeding

• Treatment with any systemic chemotherapy, epidermal growth factor receptor (EGFR) inhibitor, radiation or experimental agent within 4 weeks of study drug dosing

• Received prior cetuximab, except as defined in inclusion criteria

• Previous treatment with a phosphatidylinositol 3-kinase (PI-3K) inhibitor

• Known human immunodeficiency virus (HIV)

• Poorly controlled diabetes mellitus (IFCC-HbA1C ≥ 53 mmol/mol or DCCT -HbA1C ≥ 7%)

• Kras mutation in codon 12 or 13 (CRC patients only)

• Known or suspected clinically active brain metastases. Previously treated and stable brain metastases are allowable. Stable brain metastases are defined as no change on CT scan or MRI for minimum of two months AND no change in steroid dose for a minimum of four weeks, unless change due to intercurrent infection or other acute event)

• Any other significant medical or psychiatric condition that in the opinion of the investigator renders the patient inadequate for participation

• History of severe hypersensitivity to cetuximab